Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jean-Yves Artigou is active.

Publication


Featured researches published by Jean-Yves Artigou.


International Journal of Cardiology | 2010

Cardiac side-effects of cancer chemotherapy

Jean-Jacques Monsuez; Jean-Christophe Charniot; Noëlle Vignat; Jean-Yves Artigou

The spectrum of cardiac side-effects of cancer chemotherapy has expanded with the development of combination, adjuvant and targeted chemotherapies. Their administration in multiple regimens has increased greatly, including in older patients and in patients with cardiovascular and/or coronary artery disease (CAD). Cardiac toxicity of anthracyclines involves oxidative stress and apoptosis. Early detection combines 2D-echocardiography and/or radionuclide angiography and recent methods such as tissue Doppler imaging, strain rate echocardiography and sampling of serial troponin and/or NT-proBNP levels. Dexrazoxane has proven effective in the prevention of dose-related toxicity in children and adults. High doses of the alkylating drugs cyclophosphamide and ifosfamide may result in a reversible heart failure and in life-threatening arrhythmias. Myocardial ischemia induced by the antimetabolites 5-fluorouracil and capecitabine impacts prognosis of patients with prior CAD. Severe arrhythmias may complicate administration of microtubule inhibitors. Targeted therapies with the antibody-based tyrosine kinases (TK) inhibitors trastuzumab and, to a lesser extent, alemtuzumab induce heart failure or asymptomatic LV dysfunction in 1-4% and 10%, respectively. Cetuximab and rituximab induce hypotension, whereas bevacizumab may promote severe hypertension and venous thromboembolism. Small molecule TK inhibitors may also elicit LV dysfunction, in only few patients treated with imatinib mesylate, but in a substantially higher proportion of those receiving the multitargeted TK inhibitor sunitinib or the recently approved drugs erlotinib, lapatinib and dasatinib. Management of patients at increased cardiovascular risk associated with advancing age, previous CAD or targeted therapies may be optimized by referral to a cardiologist in a cross-specialty teamwork.


European Journal of Heart Failure | 2006

Severe dilated cardiomyopathy and quadriceps myopathy due to lamin A/C gene mutation: a phenotypic study.

Jean-Christophe Charniot; Michel Desnos; Khaled Zerhouni; Dominique Bonnefont-Rousselot; Jean-Paul Albertini; Jeffrey Zaketto Salama; Guillaume Bassez; Michel Komajda; Jean-Yves Artigou

This study reports a family affected by a new phenotype associated with dilated cardiomyopathy and quadriceps myopathy.


American Journal of Emergency Medicine | 2010

Cardiogenic shock associated with reversible dilated cardiomyopathy during therapy with regular doses of venlafaxine

Jean-Christophe Charniot; Noëlle Vignat; Jean-Jacques Monsuez; Rachid Kidouche; Boryana Avramova; Jean-Yves Artigou; Jean-Paul Albertini

We report a cardiac complication in a patient treated with regular doses of venlafaxine. A 49-year-old man with prior normal cardiac function and stable chronic hepatitis C was treated for a major depressive disorder with usual doses of venlafaxine during an 8-month period until the occurrence of a cardiogenic shock in a context of dilated cardiomyopathy. Three months after withdrawal of the drug, the left ventricular ejection fraction returned to normal values. Cardiomyopathy is a rare complication with high doses of venlafaxine that was not previously reported in patients free of prior cardiac disease and cardiomyopathy and treated with usual doses (initially 150 mg daily; after 3 months, 75 mg daily). An objective assessment revealed that venlafaxine was probably implied in the subsequent development of cardiomyopathy when considering the Naranjo Probability Scale. Physicians who usually prescribe venlafaxine have to be briefed on such potential cardiac adverse effects even with usual doses.


Free Radical Research | 2007

Oxidative stress implication in a new ex-vivo cardiac concordant xenotransplantation model.

Jean-Christophe Charniot; Dominique Bonnefont-Rousselot; Jean-Paul Albertini; Khaled Zerhouni; Sylvie Dever; Isabelle Richard; Patrick Nataf; Alain Pavie; Jean-Jacques Monsuez; Jacques Delattre; Jean-Yves Artigou

Xenotransplantation (XT) reveals a growing interest for the treatment of cardiomyopathy. The major barrier is an acute vascular rejection due to an acute humoral rejection. This pathogenesis is a difficult issue and in order to elaborate means for its prevention, we analysed the implication of oxidative stress (OS) on hearts from mini-pigs followed by reperfusion with either autologous or human blood in an attempt to simulate xenotransplantation. About 14 hearts were studied after a Langendorff blood reperfusion: allografts with autologous blood (n = 7) or xenografts with human blood (n = 7). Blood samples were drawn from the coronary sinus to assess ischemia and OS. In xenografts, arrhythmias occurred more frequently (p < 0.01, left ventricular systolic pressure decreased more significantly (p < 0.05), thiobarbituric acid-reactive substances concentrations increased at 30 min (0.7 ± 0.1 vs. 2.4 ± 0.3 mmol/l; p < 0.05) while vitamin A levels decreased (p < 0.05). XT was associated with a significant increase in ischemic injury and OS production. OS might play an eminent role in hyperacute humoral rejection.


Free Radical Research | 2007

Oxidative stress implication in a new phenotype of amyotrophic quadricipital syndrome with cardiac involvement due to lamin A/C mutation

Jean-Christophe Charniot; Dominique Bonnefont-Rousselot; C. Marchand; Khaled Zerhouni; N. Vignat; J. Peynet; M. Plotkine; A. Legrand; Jean-Yves Artigou

This study aimed at evaluating OS in an amyotrophic quadricipital syndrome with cardiac impairment in a family of 80 members with a mutation in lamin A/C gene. Twelve patients had cardiac involvement (5 cardiac and skeletal muscles impairment). OS was evaluated in blood samples (thiobarbituric acid-reactive substances (TBARS), carbonylated proteins (PCO)) 6 “affected patients” with phenotypic and genotypic abnormalities without heart failure and 3 “healthy carrier” patients. OS was higher in affected patients than in healthy, as shown by the higher TBARS and PCO values. Patients with cardiac and peripheral myopathy exhibited a higher OS than patients with only cardiac disease (TBARS: 1.73 ± 0.05 vs. 1.51 ± 0.04 mmol/l (p = 0.051), PCO: 2.73 ± 0.34 vs. 0.90 ± 0.10 nmol/mg protein (p = 0.47)), and with healthy carriers patients (TBARS: 1.73 ± 0.05 vs. 1.16 ± 0.14 mmol/l (p = 0.05), PCO: 2.73 ± 0.34 vs. 0.90 ± 0.20 nmol/mg protein (p = 0.47)). OS may thus contribute to the degenerative process of this laminopathy. ROS production occurs, prior to heart failure symptoms. We suggest that the extent activation may also promote the variable phenotypic expression of the disease.


Journal of Surgical Research | 2010

Oxidative Stress Implication After Prolonged Storage Donor Heart with Blood Versus Crystalloid Cardioplegia and Reperfusion Versus Static Storage

Jean-Christophe Charniot; Dominique Bonnefont-Rousselot; Jean-Paul Albertini; Sylvie Dever; Noëlle Vignat; Patrick Nataf; Alain Pavie; Jean-Jacques Monsuez; Jacques Delattre; Jean-Yves Artigou

Several factors are known to limit cardiac transplantation, such as number of donors, quality of cardiac graft preservation, and ischemia-reperfusion injury. Some mechanisms of reperfusion injury are now recognized; they include oxygen free radical (OFR), white blood cells activation, changes in calcium influx, alteration of microvascular blood flow, and sympathetic activation. The goal of this study was to assess the effects of two types of cardioplegia with long-term storage, either static or continuous perfusion, in 30 isolated sheep hearts as a model for heart transplantation. We examined myocardial function, histology, ischemic damage, and markers of oxidative stress. Two types of cardioplegia and storage conditions using a Langendorff reperfusion were studied in a combined approach: crystalloid (CP) [groups I and III] or cold oxygenated autologous blood (BC) [groups II and IV], immediate storage during 8h in profound hypothermia (groups I and II), or reperfused with crystalloid (group III), or blood cardioplegia (group IV). All perfusate samples were drawn from the coronary sinus. Lactate levels increased progressively in groups I, II, and IV, but not in group III, as no significant elevation was shown [90 min: 13.6+/-1.7 versus 5.2+/-1.0 mmol/L (P<0.01)]. Arrhythmias were more frequent when using BC (n=5) than CP (n=0). For plasma thiobarbituric acid-reactive substances (TBARS) levels a significant difference was found between group III and the other groups since 15 to 90 min (P<0.05). Vitamin E concentration decreased significantly from 5 min for groups II and IV, 15 min for group I, and 30 min for group III, with a significant difference between groups II and IV (P<0.05) but not between groups I and III. CP followed by a reperfusion with the same solution showed a significantly lower ischemic injury and OFR production, less frequent ventricular arrhythmias while stable hemodynamic parameters carried on. However, this protocol did not act on the early postoperative contractile function.


Heart and Vessels | 2007

Persistent symptomatic pleural effusion following coronary bypass surgery: clinical and histologic features, and treatment

Jean-Christophe Charniot; Khaled Zerhouni; Marianne Kambouchner; Emmanuel Martinod; Noëlle Vignat; Jacques F. Azorin; Iradj Gandjbakhch; Jean-Yves Artigou

Pleural effusions following coronary artery bypass grafting (CABG) have been reported in 65%–89% of the cases. The majority of pleural effusions are left-sided, of little significance, and resolve spontaneously. However, a few pleural effusions require specific therapeutics. We report clinical and pleural histologic features of three patients who had persistent post-CABG pleural effusions and underwent video-assisted thoracic surgery (VATS). These patients were studied because they had a persistent pleural effusion within the first 2 months after CABG without other identifiable causes. All patients underwent VATS for investigation and management of persistent pleural effusions. Three patients with a mean age of 63.6 ± 8.5 years were studied. The pleural effusion developed 38 ± 11.3 days after CABG (range: 22–46). The median period from CABG to VATS was 80 ± 21.6 days (range: 50–100). In all cases, the pleural effusion was large, and predominated on the left side. Pleural effusions were characterized by an exudative (n = 2) or transudative (n = 1) fluid with lymphocytosis. Histologic examination of pleural biopsies showed a follicular lymphoid hyperplasia involving the pleural serosa and a non-necrotizing granulomatous reaction with a mild inflammatory infiltrate. All patients underwent VATS with intrapleural injection of sclerosing agents. Video-assisted thoracic surgery talc pleurodesis led to symptomatic and radiologic improvement in all patients with a mean follow-up of 16.7 ± 4.5 months. No recurrence of pleural effusion has been observed in any patient. Large pleural effusions can develop in a small proportion of patients after CABG. The mechanism of pleural effusion remains unclear. Video-assisted thoracic surgery could play a significant role in the management of pleural effusion developing after CABG.


Presse Medicale | 2006

Complications cardiaques tardives de la radiothérapie

Jean-Christophe Charniot; Khaled Zerhouni; Rachid Kidouche; Linda Nascimbeni; Iradj Gandjbakhch; Jean-Yves Artigou

Resume Introduction La radiotherapie mediastinale a bouleverse le pronostic de nombre de neoplasies, en particulier les cancers du sein et les lymphomes. Cependant, avec l’augmentation de la survie, des effets secondaires sont apparus parmi lesquels les complications cardiaques, souvent tardives. Observation Il s’agit d’un patient atteint d’une maladie de Hodgkin et traite par radiotherapie. Celle-ci s’est compliquee de troubles conductifs et d’une pericardite chronique, exsudative puis constrictive, 28 ans apres la radiotherapie. Commentaires Comme en temoignent les donnees de la litterature, les complications cardiaques de la radiotherapie peuvent se succeder. Une surveillance attentive et prolongee pour une prise en charge therapeutique adaptee est necessaire.


Human Mutation | 2003

Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype.

Jean-Christophe Charniot; Cécile Pascal; Christiane Bouchier; Pascale Sébillon; Jeffrey Zaketto Salama; Laetitia Duboscq-Bidot; Mireille Peuchmaurd; Michel Desnos; Jean-Yves Artigou; Michel Komajda


Presse Medicale | 2006

Pas une… mais des hypertensions!

Noëlle Vignat; Jean-Yves Artigou

Collaboration


Dive into the Jean-Yves Artigou's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michel Desnos

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge